Urine Pyrimidine Metabolite Determination by HPLC Tandem Mass Spectrometry.

Abstract

Pyrimidine diseases result from deficiencies in pyrimidine de novo synthesis, degradation, and salvage pathways. Enzymatic deficiencies in pyrimidine catabolism lead to mitochondrial neurogastrointestinal encephalopathy (MNGIE), pyrimidinuria, dihydropyrimidinuria, ureidopropionic aciduria, and other disorders. While MNGIE presents with gastrointestinal dysmotility, cachexia, and leukoencephalopathy, pyrimidinuria and dihydropyrimidinuria may show symptoms of epilepsy, autism, mental retardation, and dysmorphic features. The application of HPLC-MS/MS facilitates rapid screening of pyrimidine metabolites. Here we describe an LCMS method for determination of uracil, thymine, thymidine, dihydrouracil, and dihydrothymine that are diagnostic biomarkers of MNGIE, pyrimidinuria, and dihydropyrimidinuria.

• Authors: Qin Sun
• Journal: Methods in molecular biology (Clifton, N.J.) (Methods Mol Biol) Vol. 1378 Pg. 237-42 ( 2016) ISSN: 1940-6029 [Electronic] United States
• PMID: 26602135 (Publication Type: Journal Article)

Chemical References

• Pyrimidines
• pyrimidine

Topics

• Chromatography, High Pressure Liquid (methods)
• Humans
• Pyrimidines (metabolism, urine)
• Tandem Mass Spectrometry (methods)
• Urinalysis (methods)